Biopharmaceuticals Contract Manufacturing Market
完整報告名稱與涵蓋範圍
Biopharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Service, By Drug Type (Biologics, Biosimilars), By Type, By Scale Of Operation (Clinical, Commercial), By Therapeutic Area, By Region, And Segment Forecasts, 2026 - 2033
報告摘要
Biopharmaceuticals Contract Manufacturing Market Summary
The global biopharmaceuticals contract manufacturing market size was valued at USD 44.7 billion in 2025 and is projected to grow from USD 50.0 billion in 2026 to USD 100.8 billion by 2033, at a CAGR of 10.5% from 2026 to 2033. North America dominated the market with the revenue share of 34.6% in 2025. The biopharmaceutical contract manufacturing market is anticipated to grow over the forecast period owing to the expanding biologics pipeline, increasing outsourcing by pharmaceutical and biotechnology companies, rising demand for monoclonal antibodies and biosimilars, growing commercial manufacturing requirements for biologics, and continuous investments in global biopharmaceutical manufacturing capacity.
The market growth is further supported by the increasing complexity of biologic manufacturing processes, stringent regulatory requirements, and the need for specialized production technologies that require substantial capital investment. These factors are encouraging drug developers to partner with contract development and manufacturing organizations for process development, clinical manufacturing, commercial production, analytical testing, and fill finish operations across multiple biologic modalities.
The expanding biologics pipeline remains one of the primary factors driving the market. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and advanced biologics, require specialized manufacturing platforms, process optimization, and regulatory-compliant production facilities that many developers choose to outsource. The growing number of biologic products advancing through clinical development is increasing demand for contract manufacturing services across both clinical and commercial stages. For instance, in May 2025, FUJIFILM Diosynth Biotechnologies announced a USD 3.2 billion expansion of its Holly Springs, North Carolina, facility to increase large-scale biologics manufacturing capacity, supporting the rising global demand for commercial production of monoclonal antibodies and other biologic therapies.
Global Biopharmaceuticals Contract Manufacturing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopharmaceuticals contract manufacturing market report based on source, service, drug type, type, scale of operation, therapeutic area, and region:
• Source Outlook (Revenue, USD Billion, 2021 - 2033)
• Mammalian
• Non-mammalian
• Service Outlook (Revenue, USD Billion, 2021 - 2033)
• Process Development
o Downstream
o Upstream
• Fill & Finish Operations
• Analytical & QC studies
• Packaging & Labelling
• Others
• Drug Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Biologics
o Monoclonal antibodies (mAbs)
o Recombinant Proteins
o Vaccines
o Antisense, RNAi, & Molecular Therapy
o Others
• Biosimilars
• Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Drug Substance
• Finished Drug Product
• Scale of Operation Outlook (Revenue, USD Billion, 2021 - 2033)
• Clinical
• Commercial
• Therapeutic Area Outlook (Revenue, USD Billion, 2021 - 2033)
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Neurology
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o UAE
o Saudi Arabia
o Kuwait
o Qatar
o Oman
授權報價
| Single User License | $5,950 USD |
| Enterprise License | $6,950 USD |
| Corporate User License | $8,950 USD |
目錄 Table of Contents
Table of Contents
Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Source
1.2.2. Service
1.2.3. Drug Type
1.2.4. Type
1.2.5. Scale of Operation
1.2.6. Therapeutic Area
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Top-Down Analysis
1.7.3. Bottom-Up Approach
1.7.4. Multivariate Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Biopharmaceuticals Contract Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rise in investment by CMOs for capacity expansion
3.2.1.2. Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
3.2.1.3. Notable growth of biologics approvals
3.2.1.4. Robust biopharmaceuticals pipeline
3.2.1.5. Cost and time-saving benefits offered by contract services
3.2.2. Market Restraint Analysis
3.2.2.1. Limited Outsourcing Amongst Well-Established Biopharmaceutical Manufacturers
3.2.2.2. Managing Relationships
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Product Pipeline Analysis
3.4. Technology Landscape
3.5. Business Model Analysis
3.6. Pricing Model Analysis
3.7. Industry Ecosystem Analysis
3.8. Tariff Impact Analysis
3.9. Market Analysis Tools
3.9.1. Porter’s Five Force Analysis
3.9.2. PESTEL Analysis
Chapter 4. Biopharmaceuticals Contract Manufacturing Market: Source Estimates & Trend Analysis
4.1. Biopharmaceuticals Contract Manufacturing Market, By Source: Segment Dashboard
4.2. Biopharmaceuticals Contract Manufacturing Market, By Source: Movement Analysis
4.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Source, 2021 - 2033 (USD Billion)
4.4. Mammalian
4.4.1. Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
4.5. Non-mammalian
4.5.1. Non-mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 5. Biopharmaceuticals Contract Manufacturing Market: Service Estimates & Trend Analysis
5.1. Biopharmaceuticals Contract Manufacturing Market, By Service: Segment Dashboard
5.2. Biopharmaceuticals Contract Manufacturing Market, By Service: Movement Analysis
5.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Service, 2021 - 2033 (USD Billion)
5.4. Process Development
5.4.1. Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.4.2. Downstream Processing
5.4.2.1. Downstream Processing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.4.3. Upstream Processing
5.4.3.1. Upstream Processing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.5. Fill & Finish Operations
5.5.1. Fill & Finish Operations Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.6. Analytical & QC Studies
5.6.1. Analytical & QC Studies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.7. Packaging & Labelling
5.7.1. Packaging & Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.8. Others
5.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 6. Biopharmaceuticals Contract Manufacturing Market: Drug Type Estimates & Trend Analysis
6.1. Biopharmaceuticals Contract Manufacturing Market, By Drug Type: Segment Dashboard
6.2. Biopharmaceuticals Contract Manufacturing Market, By Drug Type: Movement Analysis
6.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Drug Type, 2021 - 2033 (USD Billion)
6.4. Biologics
6.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.4.2. Monoclonal Antibodies
6.4.2.1. Monoclonal Antibodies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.4.3. Recombinant proteins
6.4.3.1. Recombinant Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.4.4. Vaccines
6.4.4.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.4.5. Antisense, RNAi, & Molecular Therapy
6.4.5.1. Antisense, RNAi, & Molecular Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.4.6. Others
6.4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.5. Biosimilars
6.5.1. Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 7. Biopharmaceuticals Contract Manufacturing Market: Type Estimates & Trend Analysis
7.1. Biopharmaceuticals Contract Manufacturing Market, By Type: Segment Dashboard
7.2. Biopharmaceuticals Contract Manufacturing Market, By Type: Movement Analysis
7.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Type, 2021 - 2033 (USD Billion)
7.4. Drug Substance
7.4.1. Drug Substance Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5. Finished Drug Product
7.5.1. Finished Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 8. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Estimates & Trend Analysis
8.1. Biopharmaceuticals Contract Manufacturing Market, By Scale of Operation: Segment Dashboard
8.2. Biopharmaceuticals Contract Manufacturing Market, By Scale of Operation: Movement Analysis
8.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Scale of Operation, 2021 - 2033 (USD Billion)
8.4. Clinical
8.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.5. Commercial
8.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 9. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis
9.1. Biopharmaceuticals Contract Manufacturing Market, By Therapeutic Area: Segment Dashboard
9.2. Biopharmaceuticals Contract Manufacturing Market, By Therapeutic Area: Movement Analysis
9.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Therapeutic Area, 2021 - 2033 (USD Billion)
9.4. Oncology
9.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
9.5. Autoimmune Diseases
9.5.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
9.6. Infectious Diseases
9.6.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
9.7. Cardiovascular Diseases
9.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
9.8. Metabolic Diseases
9.8.1. Metabolic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
9.9. Neurology
9.9.1. Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
9.10. Others
9.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 10. Biopharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis
10.1. Regional Market Dashboard
10.2. Regional Market Share Analysis, 2025 & 2033
10.3. North America
10.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.3.2. U.S
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Regulatory Framework
10.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.3.3. Canada
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Regulatory Framework
10.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.3.4. Mexico
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Regulatory Framework
10.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.4. Europe
10.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.4.2. UK
10.4.2.1. Key Country Dynamics
10.4.2.2. Competitive Scenario
10.4.2.3. Regulatory Framework
10.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.4.3. Germany
10.4.3.1. Key Country Dynamics
10.4.3.2. Competitive Scenario
10.4.3.3. Regulatory Framework
10.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.4.4. France
10.4.4.1. Key Country Dynamics
10.4.4.2. Competitive Scenario
10.4.4.3. Regulatory Framework
10.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.4.5. Italy
10.4.5.1. Key Country Dynamics
10.4.5.2. Competitive Scenario
10.4.5.3. Regulatory Framework
10.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.4.6. Spain
10.4.6.1. Key Country Dynamics
10.4.6.2. Competitive Scenario
10.4.6.3. Regulatory Framework
10.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.4.7. Denmark
10.4.7.1. Key Country Dynamics
10.4.7.2. Competitive Scenario
10.4.7.3. Regulatory Framework
10.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.4.8. Sweden
10.4.8.1. Key Country Dynamics
10.4.8.2. Competitive Scenario
10.4.8.3. Regulatory Framework
10.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.4.9. Norway
10.4.9.1. Key Country Dynamics
10.4.9.2. Competitive Scenario
10.4.9.3. Regulatory Framework
10.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.5. Asia Pacific
10.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.5.2. Japan
10.5.2.1. Key Country Dynamics
10.5.2.2. Competitive Scenario
10.5.2.3. Regulatory Framework
10.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.5.3. China
10.5.3.1. Key Country Dynamics
10.5.3.2. Competitive Scenario
10.5.3.3. Regulatory Framework
10.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.5.4. India
10.5.4.1. Key Country Dynamics
10.5.4.2. Competitive Scenario
10.5.4.3. Regulatory Framework
10.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.5.5. Australia
10.5.5.1. Key Country Dynamics
10.5.5.2. Competitive Scenario
10.5.5.3. Regulatory Framework
10.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.5.6. Thailand
10.5.6.1. Key Country Dynamics
10.5.6.2. Competitive Scenario
10.5.6.3. Regulatory Framework
10.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.5.7. South Korea
10.5.7.1. Key Country Dynamics
10.5.7.2. Competitive Scenario
10.5.7.3. Regulatory Framework
10.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.6. Latin America
10.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.6.2. Brazil
10.6.2.1. Key Country Dynamics
10.6.2.2. Competitive Scenario
10.6.2.3. Regulatory Framework
10.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.6.3. Argentina
10.6.3.1. Key Country Dynamics
10.6.3.2. Competitive Scenario
10.6.3.3. Regulatory Framework
10.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.7. MEA
10.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.7.2. South Africa
10.7.2.1. Key Country Dynamics
10.7.2.2. Competitive Scenario
10.7.2.3. Regulatory Framework
10.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.7.3. UAE
10.7.3.1. Key Country Dynamics
10.7.3.2. Competitive Scenario
10.7.3.3. Regulatory Framework
10.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.7.4. Saudi Arabia
10.7.4.1. Key Country Dynamics
10.7.4.2. Competitive Scenario
10.7.4.3. Regulatory Framework
10.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.7.5. Kuwait
10.7.5.1. Key Country Dynamics
10.7.5.2. Competitive Scenario
10.7.5.3. Regulatory Framework
10.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.7.6. Qatar
10.7.6.1. Key Country Dynamics
10.7.6.2. Competitive Scenario
10.7.6.3. Regulatory Framework
10.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
10.7.7. Oman
10.7.7.1. Key Country Dynamics
10.7.7.2. Competitive Scenario
10.7.7.3. Regulatory Framework
10.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 11. Competitive Landscape
11.1. Key Participant Categorization
11.1.1. Market Leaders
11.1.2. Emerging Players
11.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
11.3. Company Profiles
11.3.1. Boehringer Ingelheim GmbH
11.3.1.1. Company Overview
11.3.1.2. Financial Performance
11.3.1.3. Service Benchmarking
11.3.1.4. Strategic Initiatives
11.3.2. Lonza
11.3.2.1. Company Overview
11.3.2.2. Financial Performance
11.3.2.3. Service Benchmarking
11.3.2.4. Strategic Initiatives
11.3.3. Inno Biologics Sdn Bhd
11.3.3.1. Company Overview
11.3.3.2. Financial Performance
11.3.3.3. Service Benchmarking
11.3.3.4. Strategic Initiatives
11.3.4. Rentschler Biotechnologie GmbH
11.3.4.1. Company Overview
11.3.4.2. Financial Performance
11.3.4.3. Service Benchmarking
11.3.4.4. Strategic Initiatives
11.3.5. JRS PHARMA
11.3.5.1. Company Overview
11.3.5.2. Financial Performance
11.3.5.3. Service Benchmarking
11.3.5.4. Strategic Initiatives
11.3.6. AGC Biologics
11.3.6.1. Company Overview
11.3.6.2. Financial Performance
11.3.6.3. Service Benchmarking
11.3.6.4. Strategic Initiatives
11.3.7. ProBioGen
11.3.7.1. Company Overview
11.3.7.2. Financial Performance
11.3.7.3. Service Benchmarking
11.3.7.4. Strategic Initiatives
11.3.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
11.3.8.1. Company Overview
11.3.8.2. Financial Performance
11.3.8.3. Service Benchmarking
11.3.8.4. Strategic Initiatives
11.3.9. Toyobo Co. Ltd.
11.3.9.1. Company Overview
11.3.9.2. Financial Performance
11.3.9.3. Service Benchmarking
11.3.9.4. Strategic Initiatives
11.3.10. Samsung Biologics
11.3.10.1. Company Overview
11.3.10.2. Financial Performance
11.3.10.3. Service Benchmarking
11.3.10.4. Strategic Initiatives
11.3.11. Thermo Fisher Scientific, Inc.
11.3.11.1. Company Overview
11.3.11.2. Financial Performance
11.3.11.3. Service Benchmarking
11.3.11.4. Strategic Initiatives
11.3.12. Binex Co., Ltd.
11.3.12.1. Company Overview
11.3.12.2. Financial Performance
11.3.12.3. Service Benchmarking
11.3.12.4. Strategic Initiatives
11.3.13. WuXi Biologics
11.3.13.1. Company Overview
11.3.13.2. Financial Performance
11.3.13.3. Service Benchmarking
11.3.13.4. Strategic Initiatives
11.3.14. AbbVie, Inc.
11.3.14.1. Company Overview
11.3.14.2. Financial Performance
11.3.14.3. Service Benchmarking
11.3.14.4. Strategic Initiatives
11.3.15. ADMA Biologics, Inc.
11.3.15.1. Company Overview
11.3.15.2. Financial Performance
11.3.15.3. Service Benchmarking
11.3.15.4. Strategic Initiatives
11.3.16. Catalent, Inc.
11.3.16.1. Company Overview
11.3.16.2. Financial Performance
11.3.16.3. Service Benchmarking
11.3.16.4. Strategic Initiatives
11.3.17. Cambrex Corporation
11.3.17.1. Company Overview
11.3.17.2. Financial Performance
11.3.17.3. Service Benchmarking
11.3.17.4. Strategic Initiatives
11.3.18. Pfizer Inc.
11.3.18.1. Company Overview
11.3.18.2. Financial Performance
11.3.18.3. Service Benchmarking
11.3.18.4. Strategic Initiatives
11.3.19. Siegfried Holding AG
11.3.19.1. Company Overview
11.3.19.2. Financial Performance
11.3.19.3. Service Benchmarking
11.3.19.4. Strategic Initiatives
圖表清單 List of Tables & Figures
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Biopharmaceutical Contract Manufacturing, by Region, 2021 - 2033 (USD Billion)
Table 4 Global Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 5 Global Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 6 Global Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 7 Global Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 8 Global Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 9 Global Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 10 North America Biopharmaceutical Contract Manufacturing, by Country, 2021 - 2033 (USD Billion)
Table 11 North America Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 12 North America Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 13 North America Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 14 North America Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 15 North America Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 16 North America Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 17 U.S. Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 18 U.S. Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 19 U.S. Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 20 U.S. Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 21 U.S. Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 22 U.S. Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 23 Canada Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 24 Canada Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 25 Canada Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 26 Canada Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 27 Canada Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 28 Canada Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 29 Mexico Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 30 Mexico Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 31 Mexico Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 32 Mexico Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 33 Mexico Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 34 Mexico Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 35 Europe Biopharmaceutical Contract Manufacturing, by Country, 2021 - 2033 (USD Billion)
Table 36 Europe Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 37 Europe Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 38 Europe Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 39 Europe Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 40 Europe Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 41 Europe Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 42 Germany Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 43 Germany Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 44 Germany Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 45 Germany Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 46 Germany Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 47 Germany Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 48 UK Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 49 UK Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 50 UK Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 51 UK Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 52 UK Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 53 UK Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 54 France Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 55 France Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 56 France Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 57 France Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 58 France Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 59 France Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 60 Italy Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 61 Italy Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 62 Italy Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 63 Italy Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 64 Italy Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 65 Italy Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 66 Spain Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 67 Spain Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 68 Spain Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 69 Spain Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 70 Spain Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 71 Spain Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 72 Denmark Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 73 Denmark Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 74 Denmark Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 75 Denmark Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 76 Denmark Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 77 Denmark Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 78 Sweden Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 79 Sweden Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 80 Sweden Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 81 Sweden Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 82 Sweden Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 83 Sweden Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 84 Norway Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 85 Norway Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 86 Norway Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 87 Norway Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 88 Norway Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 89 Norway Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 90 Asia Pacific Biopharmaceutical Contract Manufacturing, by Country, 2021 - 2033 (USD Billion)
Table 91 Asia Pacific Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 92 Asia Pacific Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 93 Asia Pacific Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 94 Asia Pacific Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 95 Asia Pacific Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 96 Asia Pacific Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 97 China Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 98 China Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 99 China Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 100 China Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 101 China Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 102 China Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 103 Japan Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 104 Japan Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 105 Japan Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 106 Japan Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 107 Japan Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 108 Japan Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 109 India Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 110 India Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 111 India Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 112 India Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 113 India Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 114 India Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 115 South Korea Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 116 South Korea Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 117 South Korea Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 118 South Korea Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 119 South Korea Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 120 South Korea Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 121 Australia Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 122 Australia Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 123 Australia Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 124 Australia Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 125 Australia Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 126 Australia Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 127 Thailand Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 128 Thailand Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 129 Thailand Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 130 Thailand Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 131 Thailand Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 132 Thailand Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 133 Latin America Biopharmaceutical Contract Manufacturing, by Country, 2021 - 2033 (USD Billion)
Table 134 Latin America Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 135 Latin America Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 136 Latin America Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 137 Latin America Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 138 Latin America Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 139 Latin America Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 140 Brazil Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 141 Brazil Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 142 Brazil Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 143 Brazil Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 144 Brazil Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 145 Brazil Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 146 Argentina Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 147 Argentina Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 148 Argentina Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 149 Argentina Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 150 Argentina Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 151 Argentina Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 152 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Country, 2021 - 2033 (USD Billion)
Table 153 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 154 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 155 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 156 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 157 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 158 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 159 South Africa Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 160 South Africa Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 161 South Africa Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 162 South Africa Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 163 South Africa Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 164 South Africa Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 165 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 166 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 167 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 168 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 169 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 170 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 171 UAE Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 172 UAE Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 173 UAE Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 174 UAE Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 175 UAE Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 176 UAE Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 177 Kuwait Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 178 Kuwait Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 179 Kuwait Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 180 Kuwait Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 181 Kuwait Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 182 Kuwait Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 183 Oman Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 184 Oman Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 185 Oman Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 186 Oman Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 187 Oman Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 188 Oman Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
Table 189 Qatar Biopharmaceutical Contract Manufacturing, by Source, 2021 - 2033 (USD Billion)
Table 190 Qatar Biopharmaceutical Contract Manufacturing, by Service, 2021 - 2033 (USD Billion)
Table 191 Qatar Biopharmaceutical Contract Manufacturing, by Drug Type, 2021 - 2033 (USD Billion)
Table 192 Qatar Biopharmaceutical Contract Manufacturing, by Type, 2021 - 2033 (USD Billion)
Table 193 Qatar Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2021 - 2033 (USD Billion)
Table 194 Qatar Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2021 - 2033 (USD Billion)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD model sizing & forecasting
Fig. 9 Bottom-up approach
Fig. 10 Market snapshot
Fig. 11 Segment snapshot 1
Fig. 12 Segment snapshot 2
Fig. 13 Competitive landscape snapshot
Fig. 14 Parent market outlook, 2025 (USD Billion)
Fig. 15 Ancillary market outlook, 2025 (USD Billion)
Fig. 16 Biopharmaceuticals Contract Manufacturing Market Dynamics
Fig. 17 Porter’s five forces analysis
Fig. 18 PESTEL analysis
Fig. 19 Biopharmaceuticals Contract Manufacturing Market: Source outlook and key takeaways
Fig. 20 Biopharmaceuticals Contract Manufacturing Market: Source movement analysis
Fig. 21 Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 22 Non-mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 23 Biopharmaceuticals Contract Manufacturing Market: Service outlook and key takeaways
Fig. 24 Biopharmaceuticals Contract Manufacturing Market: Service movement analysis
Fig. 25 Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 26 Downstream Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 27 Upstream Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 28 Fill & Finish Operations Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 29 Analytical & QC studies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 30 Packaging & Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 31 Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 32 Biopharmaceuticals Contract Manufacturing Market: Drug Type outlook and key takeaways
Fig. 33 Biopharmaceuticals Contract Manufacturing Market: Drug Type movement analysis
Fig. 34 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 35 Monoclonal antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 36 Recombinant Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 37 Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 38 Antisense, RNAi, & Molecular Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 39 Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 40 Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 41 Biopharmaceuticals Contract Manufacturing Market: Type outlook and key takeaways
Fig. 42 Biopharmaceuticals Contract Manufacturing Market: Type movement analysis
Fig. 43 Drug Substance Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 44 Finished Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 45 Biopharmaceuticals Contract Manufacturing Market: Scale of Operation outlook and key takeaways
Fig. 46 Biopharmaceuticals Contract Manufacturing Market: Scale of Operation movement analysis
Fig. 47 Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 48 Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 49 Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area outlook and key takeaways
Fig. 50 Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area movement analysis
Fig. 51 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 52 Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 53 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 54 Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 55 Metabolic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 56 Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 57 Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 58 Regional Marketplace: Key Takeaways
Fig. 59 North America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 60 U.S. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 61 Canada Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 62 Mexico Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 63 Europe Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 64 UK Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 65 Germany Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 66 France Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 67 Italy Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 68 Spain Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 69 Sweden Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 70 Denmark Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 71 Norway Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 72 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 73 Japan Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 74 China Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 75 India Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 76 Thailand Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 77 South Korea Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 78 Australia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 79 Latin America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 80 Brazil Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 81 Argentina Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 82 Middle East & Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 83 South Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 84 Saudi Arabia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 85 UAE Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 86 Kuwait Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 87 Oman Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 88 Qatar Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Grand View Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們